NV INF 1
Alternative Names: Injectable FluCide™; NV-INF-1Latest Information Update: 28 Aug 2021
At a glance
- Originator NanoViricides
- Class Antivirals; Polymers
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype; Influenza A virus infections
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Influenza-A-virus-H1N1-subtype in USA (IV, Injection)
- 28 Aug 2021 No recent reports of development identified for preclinical development in Influenza-A-virus-infections in USA (IV, Injection)
- 16 Aug 2019 NV INF 1 is still in preclinical trials for Influenza A virus in USA (IV) (NanoViricides pipeline, August 2019)